Randomised, double-blind, double-dummy, two-period, cross-over study to determine the PK [pharmacokinetics], PD [pharmacodynamics] and safety of multiple doses of V1512 [melevodopa/carbidopa] effervescent tablets in Parkinson's disease patients compared to Sinemet [levodopa/carbidopa] oral tablets
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2011
At a glance
- Drugs Melevodopa/carbidopa (Primary) ; Entacapone; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Vernalis
- 31 Aug 2018 Biomarkers information updated
- 22 Jul 2011 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.